Volitionrx Ltd (VNRX)

NYSE Amex
Currency in USD
1.040
-0.040(-3.70%)
Closed
VNRX Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Trading near 52-week High
Fair Value
Day's Range
1.0401.080
52 wk Range
0.4751.080
Volitionrx Ltd is not on our AI-picked strategiesExplore current and previous stocks selected by AI
Key Statistics
Edit
Prev. Close
1.08
Open
1.06
Day's Range
1.04-1.08
52 wk Range
0.475-1.02
Volume
12.17K
Average Volume (3m)
22.65K
1-Year Change
30%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VNRX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
3.373
Upside
+224.36%
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets
No news in this category
Looks like there are no results in this news category

Volitionrx Ltd Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Compare VNRX to Peers and Sector

Metrics to compare
VNRX
Peers
Sector
Relationship
P/E Ratio
0.0x−5.7x−0.5x
PEG Ratio
0.00−0.100.00
Price/Book
0.0x1.3x2.6x
Price / LTM Sales
0.0x4.1x3.0x
Upside (Analyst Target)
0.0%173.9%54.1%
Fair Value Upside
Unlock2.5%9.4%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 3.373
(+224.36% Upside)

Earnings

Latest Release
May 08, 2024
EPS / Forecast
-- / -0.105
Revenue / Forecast
-- / 1.05M
EPS Revisions
Last 90 days
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.